1. Home
  2. ATEN vs NKTR Comparison

ATEN vs NKTR Comparison

Compare ATEN & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo A10 Networks Inc.

ATEN

A10 Networks Inc.

HOLD

Current Price

$30.09

Market Cap

2.5B

Sector

Technology

ML Signal

HOLD

Logo Nektar Therapeutics

NKTR

Nektar Therapeutics

HOLD

Current Price

$70.51

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATEN
NKTR
Founded
2004
1990
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.2B
IPO Year
2014
1996

Fundamental Metrics

Financial Performance
Metric
ATEN
NKTR
Price
$30.09
$70.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
7
Target Price
$26.33
$146.67
AVG Volume (30 Days)
1.2M
833.2K
Earning Date
04-28-2026
05-07-2026
Dividend Yield
0.90%
N/A
EPS Growth
N/A
N/A
EPS
0.17
N/A
Revenue
$235,429,000.00
$307,711,000.00
Revenue This Year
$13.02
N/A
Revenue Next Year
$10.82
N/A
P/E Ratio
$169.29
N/A
Revenue Growth
2.36
86.00
52 Week Low
$16.52
$21.02
52 Week High
$38.49
$109.00

Technical Indicators

Market Signals
Indicator
ATEN
NKTR
Relative Strength Index (RSI) 26.35 54.99
Support Level $17.00 $64.28
Resistance Level $32.95 $76.78
Average True Range (ATR) 1.54 3.57
MACD -0.98 0.17
Stochastic Oscillator 0.00 66.12

Price Performance

Historical Comparison
ATEN
NKTR

About ATEN A10 Networks Inc.

A10 Networks Inc is a provider of secure application and network infrastructure solutions for enterprises and service providers across on-premises, hybrid cloud, and distributed environments. The company's offerings include application delivery and traffic management, distributed denial-of-service (DDoS) protection, application and API security, and centralized management. It serves customers across multiple industries, including telecommunications, technology, financial services, public sector, industrial, retail, gaming, and education. The majority of the company's revenue is derived from the sale of secure networking and cybersecurity solutions and related maintenance and support services.

About NKTR Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Share on Social Networks: